Compare Chevron Corp (CVX) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs DexCom, Inc. — how do they compare? Chevron Corp trades at $196.97 (market cap $385.77B), while DexCom, Inc. trades at $89.05 (market cap $33.79B). The key difference: Chevron Corp is far larger — about 11.4× DexCom, Inc.'s market cap, and Chevron Corp pays a 3.62% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| CVX | DXCM | |
|---|---|---|
Market Cap | $385.77B | $33.79B |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $89.53 |
52-Week Low | $146.72 | $54.84 |
Enterprise Value | $414.31B | $33.24B |
Dividend Yield | 3.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $194.9, up 4.47% today, with a bullish technical signal and strong analyst support. Recent earnings consistently beat expectations, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. The company maintains solid profitability with a 9.87% net margin and 12.25% ROE, supported by a $13.8 billion investment in Argentina's Vaca Muerta shale project announced on June 2, 2026 (Reuters).
Outlook remains positive with a consensus price target of $214.25, implying 10% upside. Risks include declining revenue from $184.43B in 2025 and exposure to volatile oil prices, but high oil prices and strategic expansions provide growth catalysts. The stock offers a steady dividend of $1.78 per half-year.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
